EntryPoint Capital LLC Buys Shares of 116,645 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

EntryPoint Capital LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 116,645 shares of the company’s stock, valued at approximately $624,000.

Other hedge funds have also made changes to their positions in the company. Avity Investment Management Inc. grew its position in shares of Corvus Pharmaceuticals by 7.6% during the fourth quarter. Avity Investment Management Inc. now owns 29,680 shares of the company’s stock worth $159,000 after acquiring an additional 2,100 shares during the last quarter. Nwam LLC boosted its stake in Corvus Pharmaceuticals by 54.2% during the 4th quarter. Nwam LLC now owns 15,500 shares of the company’s stock valued at $83,000 after purchasing an additional 5,450 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Corvus Pharmaceuticals in the 4th quarter worth about $73,000. XTX Topco Ltd bought a new stake in shares of Corvus Pharmaceuticals during the third quarter valued at approximately $74,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Corvus Pharmaceuticals by 91.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 29,968 shares of the company’s stock worth $160,000 after buying an additional 14,300 shares during the period. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Price Performance

NASDAQ CRVS opened at $4.25 on Tuesday. The firm has a market capitalization of $273.09 million, a PE ratio of -4.57 and a beta of 0.91. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.30 and a 12 month high of $10.00. The company’s 50 day simple moving average is $4.72 and its 200 day simple moving average is $6.10.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.38.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.